Key result
Glimepiride is an effective once-daily insulin secretagogue for Type 2 diabetes that offers a reduced risk of hypoglycemia compared to other secretagogues, particularly in renal dysfunction.
Why the study?
Does glimepiride improve glycemic control with lower hypoglycemia risk compared to other secretagogues in patients with Type 2 diabetes mellitus?
Population
Patients with Type 2 diabetes mellitus
Comparison
Glimepiride vs Other insulin secretagogues or insulin alone
Design
Review
Authors
Loading...
May support glimepiride preference in T2DM with renal impairment; hypothesis-generating pending prospective RCTs.
Does glimepiride improve glycemic control with lower hypoglycemia risk compared to other secretagogues in patients with Type 2 diabetes mellitus?
Glimepiride is an effective once-daily sulfonylurea for Type 2 diabetes with a favorable safety profile regarding hypoglycemia and no apparent adverse effects on myocardial ischemic preconditioning.
Anthony L. McCall (2001) conducted a review in Type 2 diabetes mellitus. Glimepiride vs. Other insulin secretagogues was evaluated. Glimepiride is an effective once-daily insulin secretagogue for Type 2 diabetes that offers a reduced risk of hypoglycemia compared to other secretagogues, particularly in renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: